Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.

For the fourth time in five months, the Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Moderna brought discredit on the pharma industry. Moderna received the latest ...

I initially rated Moderna as a SELL in mid-December, and despite a recent rally, the stock remains volatile. The news flow has been great in January, which mostly caused a rally in the stock.

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other stocks. Wall Street’s main indices all finished in the green territory on Tuesday ...

Moderna is a biotechnology company primarily engaged in the development and manufacturing of messenger RNA (mRNA) medicines and vaccines. It spearheads innovation using mRNA technology to pursue ...

Moderna (NASDAQ:MRNA) traded lower in the premarket on Wednesday after Goldman Sachs downgraded the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook ...

Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

US gives conditional nod to Zoetis' bird flu vaccine for poultry Healthcare & Pharmaceuticalscategory· February 14, 2025 Moderna said on Friday that the U.S. FDA paused a late-stage trial of its ...

Moderna’s ‘Off-the-Shelf’ Cancer Vaccine Shows Promise in Early Human Trial Data The findings, published Tuesday in Nature, are important for another key reason. The team’s work originally ...